Skip to main content
. 2015 Feb 24;9:513. doi: 10.3332/ecancer.2015.513

Table 2. Clinical trials and published cases reporting use of CAM as cancer treatment in haematologic malignancies other than multiple myeloma and Waldenström’s macroglobulinemia.

Year Cancer type CAM combined with Number of patients Outcome Reference
1997 Rectal MALT lymphoma Omeprazole, amoxicillin 1 Regression confirmed pathologically [125]
1999 Low grade rectal MALT lymphoma Lansoprazole, amoxicillin 1 (H pylorinegative) Complete regression [62]
1999 Gastric MALT lymphoma Either with amoxicillin or with tetracycline 34 (28 H pyloripositive) H pylori-positive patients:
50% CR
29% PR
36% no response
H pylori-negative patients:
100% no response
[126]
2000 Low-grade gastric MALT lymphoma Omeprazole, amoxicillin 7 100% complete histologic regression [127]
2001 Low-grade gastric MALT lymphoma Omeprazole, metronidazole 97 79% CR
9% PR
11% no response
[128]
2001 High grade B-cell gastric lymphoma Omeprazole, metronidazole 8 87% CR
13% PR
[56]
2001 High grade gastric MALT lymphomas Amoxicillin, omeprazole 16 62% CR [53]
2001 Primary high grade gastric DLBCL Amoxicillin, lansoprazole 1 no evidence of lymphoma on histology [55]
2001 Low grade gastric MALT lymphoma (stage IE and IIE) Amoxicillin, lansoprazole 44 (34 H pylori-positive patients) 43% complete histological regression (56% within H pylori-positive patients) [51]
2001 Gastric DLBCL Amoxicillin, omeprazole 1 Regression [58]
2003 Gastric DLBCL Lansoprazole, metronidazole 1 CR still ongoing after 5.5 years [57]
2003 Hodgkin’s Disease of the nodular sclerotic type, stage IIb Ciprofloxacin 1 Almost complete disappearance of the pulmonary lesions after three months. Treatment continued for another five months.
More than two years later: complete remission
[61]
2003 Low-grade Thyroid MALT lymphoma Lansoprazole, amoxicillin 1 Complete disappearance of lymphoma after gastric cancer with H pyloriinfection treated by H pylorieradication therapy [63]
2004 Gastric marginal zone B cell lymphoma of MALT (stage I) Omeprazole and metronidazole or amoxicillin 95 (90 evaluable) 62% CRM
18% minimal residual disease
12% PR
4% no change
2% PD
[50]
2005 Early-stage, gastric low-grade transformed MALT lymphoma
Early-stage, gastric high-grade transformed MALT lymphoma
Amoxicillin, omeprazole
Amoxicillin, omeprazole
34 (30 patients with eradicated H pylori)
24 (22 patients with eradicated H pylori)
80% CR in patients where H pyloriwas eradicated
64% CR in patients where H pyloriwas eradicated
[54]
2006 Duodenal MALT lymphoma No other drugs 1 CR [64]
2008 B-cell gastric lymphoma (high grade) Omeprazole and amoxicillin 1
61
Complete response
69% complete response
[52]
2010 Extranodal marginal zone B-cell lymphoma (EMZL) (relapsed/ refractory) (stage IE and IV) No other drugs 13 15% CR
23% PR
31% SD
31% PD
[65]
2010 Pulmonary MALT lymphoma No other drugs 2 regression [66]
2011 Follicular B-cell lymphoma No other drugs 1 Regression of lymphadenopathy Decrease in soluble IL-2 receptor [68]
2012 Advanced CML Tyrosine kinase inhibitor 4 - 25% Complete haematologic response
-100% of patients had Bcr-abl/abl transcript level reduction
[27]
2012 H pylori positive gastric DLBCLs (de novo and MALT) stage IE/IIE1 Amoxicillin, omeprazole De novo DLBCL:
-chemo: 30
- antibiotics: 16
DLBCL (MALT): 34
De novo DLBCL
- 69% pCR
DLBCL (MALT):
- 56% pCR
[59]
2012 H pylori positive gastric DLBCL (de novoand MALT) Tinidazole, metronidazole, omeprazole 16 DLBCL of which:
-De novo: 11
- MALT: 5
50% CR
19% PR
31% PD
[60]
2012 DLBCL (stage IV) Prednisolone 1 CR after six months [69]
2013 Follicular B-cell lymphoma Prednisolone, cyclophosphamide 1 Improvement of the para-aortic lymphadenopathy, hepatomegaly and ureteral dilatation and decrease in soluble IL-2 receptor after four months which improved further after eight months [70]
2014 NHL Cyclophosphamide, vincristine and prednisone (CVP) 60 (55 evaluable) randomised in CVP and CVP+CAM CVP versus CVP+CAM
CR: 19% versus 32% (p = 0.04)
ORR: 70% versus 93% (p = 0.04)
2-year PFS: 46% versus 75% (p = 0.02) 2-year OS: 85% versus 90% (p = 0.64)
[67]

Abbreviations: MALT = mucosa-associated lymphoid tissue; CML = chronic myeloid leukaemia; DLBCL = diffuse large B-cell lymphoma; NHL = non-Hodgkin lymphoma; CR = complete response; pCR = complete pathologic remission; PR = partial response; OR = objective response; SD = Stable disease; PD = progressive disease; OS = overall survival; PFS = progression-free survival, IL-2 = interleukin-2.